CompanyGraph
Coloplast A/S
COLO.B · Nasdaq Copenhagen · Denmark
coloplast.comFinancials as of FY2024 · latest on file
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleLevered free cash flow is $1.23B, higher than 95% of all stocks globally
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.28%Below 5Y avg (2.88%)
Annual Rate
DKK 10.00Paid semi-annual
Payout Ratio
187.6%High
Last Ex-Dividend
May 18, 2026
The reported statements, read against the company's own industry.
As of FY2024 (year ended September 30, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
127.06BDKK19.84B · vs all stocks (USD)
Trailing P/E
36.26xvs Medical Instruments & Supplies peers
Revenue (TTM)
28.44BDKK4.44B · vs all stocks (USD)
Profit Margin
9.71%vs Medical Instruments & Supplies peers
52-Week Change
-28.80%vs all stocks
Forward Annual Dividend Yield
2.28%vs all stocks
Market Capitalization
127.06BDKK19.84B · vs all stocks (USD)
Enterprise Value
122.96BDKK19.20B · vs all stocks (USD)
Trailing P/E
36.26xvs Medical Instruments & Supplies peers
Forward P/E
17.04xvs Medical Instruments & Supplies peers
PEG Ratio
-0.1878xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
3.52xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
7.48xvs Medical Instruments & Supplies peers
Enterprise to Revenue
4.32xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
10.64xvs Medical Instruments & Supplies peers
Gross Margin
66.59%vs Medical Instruments & Supplies peers
Profit Margin
9.71%vs Medical Instruments & Supplies peers
Operating Margin
26.23%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
10.02%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
18.53%vs Medical Instruments & Supplies peers
Revenue (TTM)
28.44BDKK4.44B · vs all stocks (USD)
Revenue per Share (TTM)
126.22DKKUpdated Aug 21, 2026Quarterly Revenue Growth
5.70%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
19.12BDKK2.99B · vs all stocks (USD)
EBITDA (TTM)
12.08BDKK1.89B · vs all stocks (USD)
Net Income (TTM)
2.76BDKK431.53M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
81.60%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
7.67BDKK1.20B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.87BDKK1.23B · vs all stocks (USD)
Forward Annual Dividend Rate
10.00DKKUpdated Aug 21, 2026Forward Annual Dividend Yield
2.28%vs all stocks
Trailing Annual Dividend Rate
23.00DKKUpdated Aug 21, 2026Trailing Annual Dividend Yield
5.24%vs all stocks
5-Year Average Dividend Yield
2.88%vs all stocks
Payout Ratio
187.60%vs Medical Instruments & Supplies peers
Revenue
27.03BDKKFY2024 · Sep 30, 2024Cost of Goods Sold
8.76BDKKFY2024 · Sep 30, 2024Gross Profit
18.27BDKKFY2024 · Sep 30, 2024Operating Income
7.29BDKK1.14B · vs all stocks (USD)
Pre-tax Income
6.39BDKKFY2024 · Sep 30, 2024Income Tax Expense
1.34BDKKFY2024 · Sep 30, 2024Net Income
5.05BDKKFY2024 · Sep 30, 2024EBIT
7.19BDKKFY2024 · Sep 30, 2024EBITDA (Income Statement)
8.35BDKKFY2024 · Sep 30, 2024Research & Development
913.00MDKKFY2024 · Sep 30, 2024Selling, General & Administrative
10.07BDKKFY2024 · Sep 30, 2024Other Operating Expenses
76.00MDKKFY2024 · Sep 30, 2024Non-operating Interest Income
80.00MDKKFY2024 · Sep 30, 2024Non-operating Interest Expense
795.00MDKKFY2024 · Sep 30, 2024EPS (Basic)
22.46DKKFY2024 · Sep 30, 2024EPS (Diluted)
22.46DKKFY2024 · Sep 30, 2024Basic Shares Outstanding
224.90MSharesFY2024 · Sep 30, 2024Diluted Shares Outstanding
224.90MSharesFY2024 · Sep 30, 2024Net Income from Continuing Operations
7.32BDKKFY2024 · Sep 30, 2024Preferred Stock Dividends
0.00DKKFY2024 · Sep 30, 2024Operating Cash Flow
6.44BDKKFY2024 · Sep 30, 2024Free Cash Flow
5.29BDKKFY2024 · Sep 30, 2024Cash & Cash Equivalents (End of Period)
788.00MDKKFY2024 · Sep 30, 2024Starting Profit (CF Statement)
7.32BDKKFY2024 · Sep 30, 2024Other Non-cash Items
67.00MDKKFY2024 · Sep 30, 2024Change in Accounts Receivable (CF)
-661.00MDKKFY2024 · Sep 30, 2024Change in Other Assets/Liabilities
-290.00MDKKFY2024 · Sep 30, 2024Capital Expenditures
-1.15BDKKFY2024 · Sep 30, 2024Net Intangibles (CF)
-180.00MDKKFY2024 · Sep 30, 2024Net Acquisitions
8.00MDKKFY2024 · Sep 30, 2024Purchase of Investments
-13.00MDKKFY2024 · Sep 30, 2024Sale of Investments
0.00DKKFY2024 · Sep 30, 2024Net Investing Cash Flow
-1.16BDKKFY2024 · Sep 30, 2024Long-term Debt Issuance
7.82BDKKFY2024 · Sep 30, 2024Long-term Debt Payments
-4.85BDKKFY2024 · Sep 30, 2024Common Dividends Paid
-4.72BDKKFY2024 · Sep 30, 2024Net Financing Cash Flow
-1.25BDKKFY2024 · Sep 30, 2024Shares Outstanding
225.37MSharesUpdated Aug 21, 2026Float Shares
144.64MSharesUpdated Aug 21, 2026% Held by Insiders
29.79%vs all stocks
% Held by Institutions
32.64%vs all stocks
Total Cash (MRQ)
817.00MDKK127.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.63DKKUpdated Aug 21, 2026Total Debt (MRQ)
23.80BDKK3.72B · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.78xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
1.56xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
59.34DKKUpdated Aug 21, 2026Total Assets
48.07BDKK7.51B · vs all stocks (USD)
Total Current Assets
10.44BDKKFY2024 · Sep 30, 2024Total Liabilities
30.13BDKKFY2024 · Sep 30, 2024Total Non-current Assets
37.63BDKKFY2024 · Sep 30, 2024Total Non-current Liabilities
19.93BDKKFY2024 · Sep 30, 2024Total Current Liabilities
10.20BDKKFY2024 · Sep 30, 2024Cash Equivalents
788.00MDKKFY2024 · Sep 30, 2024Cash & Cash Equivalents
788.00MDKKFY2024 · Sep 30, 2024Accounts Receivable
4.67BDKKFY2024 · Sep 30, 2024Inventory
3.67BDKKFY2024 · Sep 30, 2024Accounts Payable
1.52BDKKFY2024 · Sep 30, 2024Short-term Debt
5.34BDKKFY2024 · Sep 30, 2024Other Current Liabilities
1.00MDKKFY2024 · Sep 30, 2024Long-term Debt
17.29BDKKFY2024 · Sep 30, 2024Other Non-current Liabilities
7.00MDKKFY2024 · Sep 30, 2024Common Stock (Book)
228.00MDKKFY2024 · Sep 30, 2024Retained Earnings
15.39BDKKFY2024 · Sep 30, 2024Total Shareholders' Equity
17.94BDKK2.80B · vs all stocks (USD)
52-Week Low
369.70DKKUpdated Aug 21, 202652-Week High
646.60DKKUpdated Aug 21, 202652-Week Change
-28.80%vs all stocks
50-Day MA
405.57DKKUpdated Aug 21, 2026200-Day MA
468.91DKKUpdated Aug 21, 2026Avg 10-Day Volume
239.37KSharesUpdated Aug 21, 2026Avg 30-Day Volume
301.67KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
12.24DKKUpdated Aug 21, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Levered free cash flow is $1.23B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 1,229,917,470.013Global P95: 1,123,592,359.78
Market cap is $19.84B, above the global median of $1.15BNotable
Market cap (USD): 19,844,511,507.156Global Median: 1,146,734,693.424
Revenue is $4.44B, above the global median of $520.53MNotable
Revenue (USD): 4,442,071,460.045Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
International Paper Company
Tier 1ProductionThroughput-Bound ConversionFlowRule
Straumann Holding AG
Tier 1ProductionThroughput-Bound ConversionRule
Ruijie Networks Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Hyosung Heavy Industries Corporation
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Fortum Oyj
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Amcor plc
Tier 1ProductionThroughput-Bound ConversionFlowRule
China Longyuan Power Group Corporation Limited
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Knorr-Bremse AG
Tier 1ProductionThroughput-Bound ConversionRiskRule
MACOM Technology Solutions Holdings, Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Hd Hyundai Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Vedant Fashions Ltd.
8 interpretationsFCF Ratios ElevatedReceivables Heavy and GrowingROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
Coloplast A/S Class B
8 interpretationsFCF Ratios ElevatedReceivables Heavy and GrowingROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
United States Lime & Minerals Inc.
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin